XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
2. Fair Value Measurements 2. Contingent Consideration (Details) - USD ($)
$ in Millions
 3 Months Ended 16 Months Ended 33 Months Ended
Mar. 31, 2018
Mar. 31, 2018
Dec. 31, 2020
Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value $ 13.3 $ 13.3   $ 16.7
Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Contingent consideration milestone payments (1.3)      
Business Combination, Contingent Consideration, Liability 13.3 13.3    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances $ (2.1) $ (8.2)    
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Acquisition, Contingent Consideration, Potential Percentage Payout 39.00% 39.00%    
Market Price of Risk [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value Inputs, Entity Credit Risk 10.80%      
Projected Volatility of Growth Rate [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair Value Inputs, Entity Credit Risk 4.60%      
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Acquisition, Contingent Consideration, Potential Percentage Payout 20.00% 20.00%    
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low $ 0.0 $ 0.0    
Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration, Liability [1] 13.3 13.3   16.7
Other Noncurrent Liabilities [Member] | Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration, Liability 10.1 10.1   14.0
Other Current Liabilities [Member] | Fair Value, Measurements, Recurring [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration, Liability $ 3.2 $ 3.2   $ 2.7
Scenario, Forecast [Member] | Analytical Flow Cytometer Platform [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High     $ 66.8  
[1] Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions):

 
March 31, 2018
 
December 31, 2017
Other current liabilities
$
3.2

 
$
2.7

Other long-term liabilities
10.1

 
14.0

   Total
$
13.3

 
$
16.7